CAS: 60832-72-6; Oxazolo[4,5-B]Pyridin-2(3H)-One

相似化合物

55656-25-2 21594-52-5 35570-68-4

上下游产品

CAS号16867-03-1 2-氨基-3-羟基吡啶 | CAS号530-62-1 N,N'-羰基二咪唑(CDI) | CAS号15128-82-2 3-羟基-2-硝基吡啶 | CAS号201230-82-2 carbon monoxide | CAS号933-90-4 3-羟基吡啶酰胺 | CAS号32315-10-9 三光气 | CAS号74124-79-1 N,N'-二琥珀酰亚胺基碳酸酯 | CAS号32276-00-9 bis[(1-phenylte... | CAS号57-13-6 尿素 | CAS号75-15-0 二硫化碳 | CAS号35575-96-3 甲基吡啶磷 | CAS号35570-68-4 6-氯恶唑并[4,5-b]吡啶... | CAS号39903-01-0 2-羟基-3-氨基-5-溴吡啶 | CAS号21594-54-7 6-硝基噁唑并[4,5-b]吡... | CAS号35570-69-5 6-chloro-3-(hyd... | CAS号35570-72-0 3-[2-(4-chlorop... | CAS号35570-65-1 3-[[4-[[4-[(3-s... | CAS号134336-95-1 3-(2-溴乙基)恶唑并[4,... | CAS号174469-41-1 6-bromo-2-pheny... | CAS号21594-52-5 6-溴-3H-恶唑并[4,5-...

3-羟基吡啶酰胺置于氢氧化钾,碘苯二乙酸体系中,用 甲醇 作为反应溶剂,化学反应 1.0H,以68%的收率获得产物2,3-二氢吡啶并[2,3-D][1,3]噁唑-2-酮
参考文献:邻氨基苯甲酰胺,水杨酰胺和一些β-取代酰胺的高价碘氧化重排:2-苯并咪唑酮,2-苯并恶唑酮和相关化合物的新型便捷合成
标题:邻氨基苯甲酰胺,水杨酰胺和一些β-取代酰胺的高价碘氧化重排:2-苯并咪唑酮,2-苯并恶唑酮和相关化合物的新型便捷合成
摘要:在甲醇氢氧化钾中用碘苯二乙酸酯氧化邻氨基苯甲酰胺,水杨酰胺和一些β-取代的酰胺,分别导致2-苯并咪唑酮,2-苯并恶唑酮和相关化合物的新且方便的合成.该反应可能通过最初的霍夫曼型重排发生,然后是中间体异氰酸酯的分子内环化.
DOI:10.1055/s-2001-12346

专利信息

专利号:US-8785632-B2
优先权日:2004-08-26
标 题:Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
发明人：CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE
权利人:CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE; AGOURON PHARMA; PFIZER
摘要:Enantiomerically pure compound of formula 1 n nare provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

专利号:US-2006178374-A1
优先权日:2004-08-26
标 题 :Aminoheteroaryl compounds as protein kinase inhibitors
发明人：CUI JINGRONG J; FUNK LEE A; JIA LEI; KUNG PEI-PEI; MENG JERRY J; NAMBU MITCHELL D; PAIRISH MASON A; SHEN HONG; TRAN-DUBE MICHELLE
权利人:AGOURON PHARMA
摘要:Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.